Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cilomilast · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| cilomilast | DRUG | - |
Inclusion criteria: * Diagnosis of COPD and a history of cigarette smoking. Exclusion criteria: * Significant heart or lung disease not associated with COPD. * Significant stomach or intestinal disease.
Cilomilast is an investigational small molecule developed for chronic obstructive pulmonary disease (COPD), a respiratory condition. It was studied in adults aged 40 years and older with COPD. Cilomilast has not been approved for marketing and remains in clinical development for this indication.
Cilomilast is a phosphodiesterase 4 (PDE4) inhibitor. It targets the PDE4 enzyme subtypes PDE4A, PDE4B, PDE4C, and PDE4D. By inhibiting these enzymes, cilomilast is designed to modulate inflammatory signaling associated with chronic obstructive pulmonary disease.
Cilomilast is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the clinical development program for the drug in chronic obstructive pulmonary disease.
Cilomilast reached Phase 3 clinical development for chronic obstructive pulmonary disease. It is an investigational drug and has not been approved by the FDA. The Phase 3 trial evaluating it has been completed.
Cilomilast was evaluated in the Phase 3 trial NCT00103922, titled Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease). The trial enrolled 600 participants, was randomized and double blind, and was conducted in the United States. It is listed as completed, with no active trials ongoing.